Axoft announced promising preliminary results from the first-in-human study of its implantable brain-computer interface (iBCI) technology using Fleuron, a breakthrough ultrasoft material.
The Cambridge, Massachusetts-based company launched its FINESSE study just two and a half years after its seed round. Fleuron is 10,000 times softer than conventional polyimide materials, offering enhanced biocompatibility, minimal brain tissue disruption, and long-term signal stability. Early clinical data from four patients showed high-quality, stable neural recordings across cortical and subcortical regions.
Dr. Ricardo Bermúdez, principal investigator, called it “leapfrog technology” compared to rigid electrodes currently used in neurosurgery.
Follow MEDWIRE.AI for updates on brain-computer interface innovation.
